Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy
📧 Sign up to get email alerts when something new happens for Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy [Phase 3]
A Phase 3 trial (TRITON-PN) evaluating Nucresiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy is currently recruit…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Phase 3 Study of NTLA-2001 in ATTRv-PN [Phase 3]
NTLA-2001, Intellia's in vivo gene-editing therapy, is in Phase 3 for hereditary transthyretin-mediated amyloidosis with polyneuropathy and …
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
An observational study is evaluating neurofilament light chain as a biomarker in asymptomatic carriers of transthyretin variants and in pati…
-
CLINICAL_TRIALS research · 2025-06-29Clinical Trial Update: TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
This clinical trial update describes the TRAMmoniTTR study, a genetic screening program for individuals at risk of hereditary transthyretin …